Streetbeat News

Stock Prices

CYTH

Cyclo Therapeutics (NASDAQ:CYTH) reported Q2 earnings per share (EPS) of $(0.21), missing the analyst estimate of $(0.16) by 31.25%. Sales were $123.10K, missing the estimate of $267.50K by 53.98%. Despite the misses, EPS improved by 36.36% and sales increased by 5.11% year-over-year.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 1:03 pm

SPCB

SuperCom reported Q2 2024 adjusted EPS of $0.09, significantly beating the estimate of $(0.03). Sales for the quarter were $7.545 million, also surpassing the $6.000 million estimate.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 1:02 pm

SIGA

The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) announced that SIGA Technologies' antiviral tecovirimat did not meet its primary endpoint in a study for treating monkeypox virus in the Democratic Republic of the Congo. The study showed no statistically significant improvement in lesion resolution within 28 days. SIGA's stock dropped 38.3% following the news.

Portfolio Pulse from Vandana Singh

August 15, 2024 | 1:01 pm

ALGS

Aligos Therapeutics has announced a 1-for-25 reverse stock split effective August 19, 2024. The company's common stock will begin trading on the Nasdaq Capital Market under the symbol ALGS with a new CUSIP number 01626L 204.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 1:01 pm

AVDE

AVSD

UBS

UBS Group AG has placed a $2 billion Credit Suisse real estate fund into liquidation due to significant value decline and high redemptions. UBS reported strong Q2 FY24 sales and EPS, beating consensus estimates. UBS shares are down 2.33% premarket.

Portfolio Pulse from Lekha Gupta

August 15, 2024 | 1:00 pm

WELL

Analysts have provided mixed ratings for Welltower (NYSE:WELL) over the past three months, with a recent increase in average price targets. The company's financial performance has been strong, with notable revenue growth, net margin, and efficient debt management.

Portfolio Pulse from Benzinga Insights

August 15, 2024 | 1:00 pm

GILD

Over the past three months, 8 analysts have shared their insights on Gilead Sciences (NASDAQ:GILD), with opinions ranging from bullish to bearish. The average 12-month price target has increased to $77.25 from $74.86. Key analysts have adjusted their ratings and price targets, reflecting their responses to recent developments. Gilead Sciences shows strong financial metrics, including a net margin of 23.21% and a return on equity of 9.01%.

Portfolio Pulse from Benzinga Insights

August 15, 2024 | 1:00 pm

GLBE

Over the past three months, 12 analysts have shared their evaluations of Global E Online (NASDAQ:GLBE), with a mix of bullish and somewhat bullish ratings. The average 12-month price target is $44.42, slightly up from the previous $44.09. Analysts have adjusted their ratings and price targets based on recent developments, reflecting a generally positive outlook for the company.

Portfolio Pulse from Benzinga Insights

August 15, 2024 | 1:00 pm

RSKD

Analysts have provided mixed ratings for Riskified (NYSE:RSKD) over the past three months, with a recent average 12-month price target of $6.25, reflecting a 4.17% increase from the previous target. Key analysts from Piper Sandler, Goldman Sachs, UBS, and Barclays have adjusted their ratings and price targets, indicating varied expectations for the company's future performance.

Portfolio Pulse from Benzinga Insights

August 15, 2024 | 1:00 pm

OMGA

Over the past three months, four analysts have evaluated Omega Therapeutics (NASDAQ:OMGA), with ratings ranging from bullish to bearish. The average 12-month price target is $10.5, with a high of $12.00 and a low of $6.00. Recent ratings include 'Buy' and 'Outperform' from HC Wainwright & Co., Wedbush, and Raymond James, while Chardan Capital lowered its target from $7.00 to $6.00. Omega Therapeutics has shown significant revenue growth but faces challenges with high debt levels and low ROE.

Portfolio Pulse from Benzinga Insights

August 15, 2024 | 1:00 pm